Cargando…

A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth

BACKGROUND: Antiangiogenic therapies have been proven effective in cancer treatment. Fibroblast growth factor-2 (FGF-2) has been functionally implicated in tumour angiogenesis and is an important target of antiangiogenic therapies. The aim of this work was to develop a novel FGF-2 inhibitor for canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, D, Wei, X, Xie, K, Chen, K, Li, J, Fang, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090743/ https://www.ncbi.nlm.nih.gov/pubmed/24874473 http://dx.doi.org/10.1038/bjc.2014.282

Ejemplares similares

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours
por: Zhang, X, et al.
Publicado: (2014)

Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells
por: Chakraborty, S, et al.
Publicado: (2011)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
por: Lamont, F R, et al.
Publicado: (2011)

Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways
por: Hu, X F, et al.
Publicado: (2007)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
por: Soh, C-L, et al.
Publicado: (2014)

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells
por: Byron, S A, et al.
Publicado: (2006)

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer
por: Barnes, N L P, et al.
Publicado: (2007)

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells
por: Thiel, U, et al.
Publicado: (2011)

Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response
por: Domanitskaya, N, et al.
Publicado: (2014)

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling
por: Weidenaar, A C, et al.
Publicado: (2011)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
por: Farooqui, M, et al.
Publicado: (2007)

A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice
por: Wehenkel, M, et al.
Publicado: (2012)

New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
por: Sorriento, D, et al.
Publicado: (2015)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
por: Yen, W-C, et al.
Publicado: (2006)

Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice
por: Lorch, G, et al.
Publicado: (2007)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2)
por: Olea-Herrero, N, et al.
Publicado: (2009)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells
por: Sinclair, A M, et al.
Publicado: (2008)

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
por: Jin, L, et al.
Publicado: (2011)

Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235)
por: Trauger, R, et al.
Publicado: (2009)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kn1kbkafsn32hpj3ol9de9vvvp